Cargando…

Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients

Large size, protein binding and intracellular sequestration are well known to limit dialytic removal of compounds. In studying the normal renal and dialytic handling of trimethylamine oxide (TMAO), a molecule associated with cardiovascular disease in the general population, we discovered two largely...

Descripción completa

Detalles Bibliográficos
Autores principales: Hai, Xin, Landeras, Veeda, Dobre, Mirela A., DeOreo, Peter, Meyer, Timothy W., Hostetter, Thomas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674074/
https://www.ncbi.nlm.nih.gov/pubmed/26650937
http://dx.doi.org/10.1371/journal.pone.0143731
_version_ 1782404853336637440
author Hai, Xin
Landeras, Veeda
Dobre, Mirela A.
DeOreo, Peter
Meyer, Timothy W.
Hostetter, Thomas H.
author_facet Hai, Xin
Landeras, Veeda
Dobre, Mirela A.
DeOreo, Peter
Meyer, Timothy W.
Hostetter, Thomas H.
author_sort Hai, Xin
collection PubMed
description Large size, protein binding and intracellular sequestration are well known to limit dialytic removal of compounds. In studying the normal renal and dialytic handling of trimethylamine oxide (TMAO), a molecule associated with cardiovascular disease in the general population, we discovered two largely unrecognized additional limitations to sustained reduction of a solute by chronic hemodialysis. We measured solute levels and handling in subjects on chronic hemodialysis (ESRD, n = 7) and compared these with levels and clearance in normal controls (NLS, n = 6). The ESRD patients had much higher peak predialysis plasma levels of TMAO than NLS (77 ± 26 vs 2±1 μM, mean ± SD, p<0.05). For comparison, predialysis BUN levels in ESRD subjects were 45±11 mg/dl and 15±3 mg/dl in NLS. Thus TMAO levels in ESRD average about 40 fold those in NLS while BUN is 3 fold NLS. However, the fractional reduction of TMAO concentration during dialysis, was in fact greater than that of urea (86±3 vs 74±6%, TMAO vs urea, p < 0.05) and its dialytic clearance while somewhat lower than that of urea was comparable to creatinine’s. Also production rates were similar (533±272 vs 606 ± 220 μ moles/day, ESRD vs NLS, p>0.05). However, TMAO has a volume of distribution about one half that of urea. Also in NLS the urinary clearance of TMAO was high (219±78 ml/min) compared to the urinary urea and creatinine clearances (55±14 and 119±21 ml/min, respectively). Thus, TMAO levels achieve multiples of normal much greater than those of urea due mainly to 1) TMAO’s high clearance by the normal kidney relative to urea and 2) its smaller volume of distribution. Modelling suggests that only much more frequent dialysis would be required to lower levels Thus, additional strategies such as reducing production should be explored. Furthermore, using urea as the sole marker of dialysis adequacy may be misleading since a molecule, TMAO, that is dialyzed readily accumulates to much higher multiples of normal with urea based dialysis prescriptions.
format Online
Article
Text
id pubmed-4674074
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46740742015-12-23 Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients Hai, Xin Landeras, Veeda Dobre, Mirela A. DeOreo, Peter Meyer, Timothy W. Hostetter, Thomas H. PLoS One Research Article Large size, protein binding and intracellular sequestration are well known to limit dialytic removal of compounds. In studying the normal renal and dialytic handling of trimethylamine oxide (TMAO), a molecule associated with cardiovascular disease in the general population, we discovered two largely unrecognized additional limitations to sustained reduction of a solute by chronic hemodialysis. We measured solute levels and handling in subjects on chronic hemodialysis (ESRD, n = 7) and compared these with levels and clearance in normal controls (NLS, n = 6). The ESRD patients had much higher peak predialysis plasma levels of TMAO than NLS (77 ± 26 vs 2±1 μM, mean ± SD, p<0.05). For comparison, predialysis BUN levels in ESRD subjects were 45±11 mg/dl and 15±3 mg/dl in NLS. Thus TMAO levels in ESRD average about 40 fold those in NLS while BUN is 3 fold NLS. However, the fractional reduction of TMAO concentration during dialysis, was in fact greater than that of urea (86±3 vs 74±6%, TMAO vs urea, p < 0.05) and its dialytic clearance while somewhat lower than that of urea was comparable to creatinine’s. Also production rates were similar (533±272 vs 606 ± 220 μ moles/day, ESRD vs NLS, p>0.05). However, TMAO has a volume of distribution about one half that of urea. Also in NLS the urinary clearance of TMAO was high (219±78 ml/min) compared to the urinary urea and creatinine clearances (55±14 and 119±21 ml/min, respectively). Thus, TMAO levels achieve multiples of normal much greater than those of urea due mainly to 1) TMAO’s high clearance by the normal kidney relative to urea and 2) its smaller volume of distribution. Modelling suggests that only much more frequent dialysis would be required to lower levels Thus, additional strategies such as reducing production should be explored. Furthermore, using urea as the sole marker of dialysis adequacy may be misleading since a molecule, TMAO, that is dialyzed readily accumulates to much higher multiples of normal with urea based dialysis prescriptions. Public Library of Science 2015-12-09 /pmc/articles/PMC4674074/ /pubmed/26650937 http://dx.doi.org/10.1371/journal.pone.0143731 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Hai, Xin
Landeras, Veeda
Dobre, Mirela A.
DeOreo, Peter
Meyer, Timothy W.
Hostetter, Thomas H.
Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients
title Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients
title_full Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients
title_fullStr Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients
title_full_unstemmed Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients
title_short Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients
title_sort mechanism of prominent trimethylamine oxide (tmao) accumulation in hemodialysis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674074/
https://www.ncbi.nlm.nih.gov/pubmed/26650937
http://dx.doi.org/10.1371/journal.pone.0143731
work_keys_str_mv AT haixin mechanismofprominenttrimethylamineoxidetmaoaccumulationinhemodialysispatients
AT landerasveeda mechanismofprominenttrimethylamineoxidetmaoaccumulationinhemodialysispatients
AT dobremirelaa mechanismofprominenttrimethylamineoxidetmaoaccumulationinhemodialysispatients
AT deoreopeter mechanismofprominenttrimethylamineoxidetmaoaccumulationinhemodialysispatients
AT meyertimothyw mechanismofprominenttrimethylamineoxidetmaoaccumulationinhemodialysispatients
AT hostetterthomash mechanismofprominenttrimethylamineoxidetmaoaccumulationinhemodialysispatients